Strictly private & confidential
Every 35 seconds an IVF baby is born. Each began with a person choosing an embryo by eye.
Fertificially is the second pair of eyes — an adjunctive AI blastocyst assessment tool being taken through the FDA. Enter your details and accept the confidentiality agreement to continue.
  • $2.0M seed · post-money SAFE · single close Q4 2026
  • Full diligence pack — regulatory, clinical, financial, legal
  • Product walkthrough and the complete figure register inside
  • Every page confidential, view-only and watermarked to you
ClariaDX LLC · Miami, Florida Himanshu Arora, Ph.D · Co-Founder & Co-CEO
h.arora@clariadx.com · www.fertificially.com ↗
Request access · Step 1 of 2
Your details & the confidentiality agreement
Enter your information below. The agreement fills in with your details as you type — no paperwork, no printing. Accepting is a binding electronic signature.
Non-Disclosure & Confidentiality Agreement
Auto-filled · Florida law

This Non-Disclosure & Confidentiality Agreement (this “Agreement”) is entered into and effective as of the date of acceptance, by and between ClariaDX LLC, a Florida limited liability company with its principal office at 6240 SW 108th Place, Miami, Florida 33173 (the “Company”), and [your name] (the “Recipient”), reachable at [your email].

1 · Confidential Information

The Recipient will receive the Company's investor deck, business plan, financial model, and regulatory, clinical, technical, intellectual-property and legal materials relating to the Fertificially platform (the “Confidential Information”), disclosed solely so the Recipient may evaluate a potential investment in the Company or its corporate successor (the “Permitted Purpose”).

2 · Non-use & permitted recipients

The Recipient will use the Confidential Information only for the Permitted Purpose and will disclose it only to the Recipient's advisors and fund colleagues on a need-to-know basis, each bound by confidentiality obligations at least as protective as these. The Recipient will not reverse-engineer, benchmark or attempt to derive the Company's models, data or methods from the Confidential Information.

3 · Independent evaluation

Nothing here restricts the Recipient from evaluating or investing in other companies, provided the Confidential Information is not used or disclosed.

4 · No offer of securities

The Confidential Information is provided for information only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any offering will be made only to accredited investors through definitive transaction documents in reliance on an applicable exemption from registration.

5 · Term

The Recipient's confidentiality obligations continue for three (3) years from the date of acceptance; obligations relating to trade secrets continue for so long as the information remains a trade secret.

6 · Governing law & disputes

This Agreement is governed by the laws of the State of Florida, without regard to its conflict-of-laws rules. Any dispute will be resolved by binding arbitration in Miami-Dade County, Florida, under the rules of the American Arbitration Association.

7 · Recipient representations & acknowledgments

The Recipient represents and acknowledges that: (a) it received access to these materials through a direct, personal communication and not as a result of any general solicitation, public advertisement, or offer made to the public; (b) it is a sophisticated party able to evaluate and bear the risks of a potential investment of this nature and qualifies as an “accredited investor” within the meaning of Rule 501(a) of Regulation D under the U.S. Securities Act of 1933, or is otherwise eligible under applicable law; (c) it is reviewing these materials solely to evaluate a potential investment for its own account; (d) it understands these materials are not an offer to sell or a solicitation to buy any security; and (e) it will not forward, post, or otherwise make these materials or the access link available to the public or to anyone other than its own advisors on a need-to-know basis.

8 · Electronic acceptance

By typing your name and clicking “Agree & enter,” you confirm you are authorised to accept on behalf of the Recipient and that your typed name and click constitute a valid, binding electronic signature under the U.S. Electronic Signatures in Global and National Commerce Act and the Florida Uniform Electronic Transaction Act.

⚠ Important notices — please read before entering
Not an offer. This material is for information only and is not an offer to sell or a solicitation to buy any security. Any offer will be made solely through definitive transaction documents to accredited investors.
High-risk & illiquid. Investing in an early-stage private company is speculative and illiquid; you could lose your entire investment. Peer funding figures shown are context only, not a prediction.
Forward-looking. Projections, timelines, regulatory pathways and the financial model are forward-looking and subject to significant uncertainty; actual results may differ materially.
Investigational device. Fertificially is not cleared or approved by the U.S. FDA or any regulator. No clinical performance claim is made; it is not an embryo selector and does not predict implantation or live birth.
No reliance. Information is provided “as is,” without representation or warranty. Conduct your own due diligence and consult your own legal, tax and investment advisors.
Confidential. Provided under NDA for your evaluation only — do not copy, forward or distribute. Full disclosures, including related-party and intellectual-property matters, are inside the room.
Your signature appears here
This acceptance will be recorded as: [complete the form above] · with timestamp and IP, for the Company's records.
Verify your email · Step 2 of 2
Enter your 6-digit code
To confirm it's really you, we emailed a 6-digit code to your email. Enter it below to open the room. The code expires in 10 minutes.
Didn't get it? Check spam, or resend the code.